Interleukin-6: From identification of the cytokine to development of targeted treatments
| Autor: | Jean-Michel Dayer, Eric Assier, Marie-Christophe Boissier |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.drug_class
medicine.medical_treatment Pharmacology Antibodies Monoclonal Humanized Monoclonal antibody Arthritis Rheumatoid Mice chemistry.chemical_compound Tocilizumab Rheumatology Cytokine Receptor gp130 medicine Animals Humans Molecular Targeted Therapy Interleukin 6 Receptor biology Interleukin-6 business.industry Antibodies Monoclonal Glycoprotein 130 Disease Models Animal Cytokine chemistry Antirheumatic Agents Interleukin-6 Receptor alpha Subunit Monoclonal biology.protein Signal transduction business Signal Transduction |
| Zdroj: | Joint Bone Spine. 77:532-536 |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2010.07.007 |
| Popis: | Interleukin-6 (IL-6) was identified based on extensive research conducted simultaneously on a variety of topics ranging from hepatocyte production of acute-phase proteins to plasmacytoma growth. IL-6 is a cytokine produced by a broad array of cell types and can exert its effects on virtually all cells. IL-6 can induce cell signaling not only via the classic pathway involving the transmembrane receptor IL-6Rα (restricted cellular expression) associated with gp130 (ubiquitous and responsible for signal transmission), but also via the soluble receptor IL-6Rα, which binds to IL-6 and induces a signal mediated by the ubiquitous gp130 molecule (transsignaling). IL-6 is deregulated in many inflammatory and autoimmune diseases, including rheumatoid arthritis (RA). By virtue of its multiple effects, IL-6 is involved in the various phases of RA development, including the acute phase, immuno-inflammatory phase, and destructive phase. IL-6 has an impact on the many pathogenic factors identified in RA and, consequently, holds promise for targeted treatments. However, anti-IL-6 monoclonal antibodies evaluated as IL-6 antagonists, instead, increased the half-life of the cytokine. In contrast, monoclonal antibody (tocilizumab) to transmembrane and soluble IL-6Rα has been found effective in patients with RA. Tocilizumab is now indicated for the treatment of adults with RA who have failed at least one synthetic disease-modifying antirheumatic drug or TNFα antagonist. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect